Skip to main content
Journal cover image

Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients.

Publication ,  Journal Article
Merseburger, AS; Connelly, RR; Sun, L; Richter, E; Moul, JW
Published in: Urology
November 2001

OBJECTIVES: To assess serum creatinine as a putative marker for staging/prognosis in localized prostate cancer. Although clinical stage, tumor grade, serum prostate-specific antigen (PSA), and tumor volume assessment by biopsy positivity are established prognostic markers in prostate cancer, the need for additional serum markers is clear. In a prior neural network analysis by our group, serum creatinine appeared to improve staging and prognosis. Even though serum creatinine is one of the most common blood tests used by practicing urologists, it has not been tested rigorously as a potential staging/prognosis marker in localized prostate cancer. METHODS: The data on 409 patients who underwent radical prostatectomy at the Walter Reed Army Medical Center between 1990 and 1996 were analyzed. Logistic regression analysis was used to evaluate the ability of serum creatinine to predict the pathologic stage. The ability of creatinine to predict PSA recurrence was also assessed using Cox regression analysis. In multivariable analyses, creatinine was assessed while simultaneously controlling for race, age, prostate weight, clinical stage, Gleason (World Health Organization) grade, prostatism history, treatment of benign prostatic hyperplasia, and pretreatment PSA level. RESULTS: Creatinine ranged from 0.1 to 2.3 mg/dL (mean and median 1.1 mg/dL). The relationship of creatinine to pathologic stage was significant (P = 0.050). As the level of creatinine increased, the proportion of patients with extraprostatic disease generally decreased. In multivariable logistic regression analysis, creatinine was not a significant predictor (P = 0.270). The relationship of the creatinine level to PSA recurrence was not significant in the univariate or multivariable analysis. CONCLUSIONS: Creatinine did not provide independent information for predicting pathologic stage or disease recurrence in patients with early prostate cancer.

Duke Scholars

Published In

Urology

DOI

EISSN

1527-9995

Publication Date

November 2001

Volume

58

Issue

5

Start / End Page

729 / 734

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Retrospective Studies
  • Regression Analysis
  • Prostatic Neoplasms
  • Prostatectomy
  • Prostate-Specific Antigen
  • Prostate
  • Prognosis
  • Organ Size
  • Neoplasm Staging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Merseburger, A. S., Connelly, R. R., Sun, L., Richter, E., & Moul, J. W. (2001). Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. Urology, 58(5), 729–734. https://doi.org/10.1016/s0090-4295(01)01370-x
Merseburger, A. S., R. R. Connelly, L. Sun, E. Richter, and J. W. Moul. “Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients.Urology 58, no. 5 (November 2001): 729–34. https://doi.org/10.1016/s0090-4295(01)01370-x.
Merseburger AS, Connelly RR, Sun L, Richter E, Moul JW. Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. Urology. 2001 Nov;58(5):729–34.
Merseburger, A. S., et al. “Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients.Urology, vol. 58, no. 5, Nov. 2001, pp. 729–34. Pubmed, doi:10.1016/s0090-4295(01)01370-x.
Merseburger AS, Connelly RR, Sun L, Richter E, Moul JW. Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. Urology. 2001 Nov;58(5):729–734.
Journal cover image

Published In

Urology

DOI

EISSN

1527-9995

Publication Date

November 2001

Volume

58

Issue

5

Start / End Page

729 / 734

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Retrospective Studies
  • Regression Analysis
  • Prostatic Neoplasms
  • Prostatectomy
  • Prostate-Specific Antigen
  • Prostate
  • Prognosis
  • Organ Size
  • Neoplasm Staging